Gilles Guillemin

Neurodegenerative diseases group (Gilles Guillemin, Ph.D.)

See personal website for more information http://www.drgillesguillemin.com

Introduction

Astrocytes_GFAP

Dr Guillemin is studying the involvement of the tryptophan catabolism (via the kynurenine pathway) in several neurodegenerative diseases. He has demonstrated the importance of the kynurenine pathway in Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, which has opened very promising research opportunities and has important therapeutic potential. He has extended his research to other diseases such as Parkinson’s disease and brain tumours.

 

This research has been the focus of national and international collaborations that have led to several grants.

Dr Guillemin is currently leading a research group of 15 people including 2 visiting scientists, 1 post-doc, 7 PhD students 3 Honours students and 1 Masters student.

List of current projects:

  1. The involvement of the kynurenine pathway and the neurotoxin quinolinic acid in the pathogenesis of Alzheimer’s disease (post-doc: Wei WU)
  2. Involvement of the kynurenine pathway in the persistence of childhood and adult brain tumours. (PhD Student: Seray ADAMS)
  3. The involvement of quinolinic acid and other tryptophan catabolites in the neuropathology of amyotrophic lateral sclerosis. (PhD Student: Jon-Ming Lee)
  4. Development of a new treatment for multiple sclerosis based on the alteration of Tryptophan metabolism (PhD Students: Edwin LIM & Gayathri SUNDARAM)
  5. Involvement of the kynurenine pathway in Parkinson’s disease (PhD Student: Anna ZINGER)
  6. NAD+ Metabolism in Aging and Degenerative Diseases. (PhD Student: Nady BRAIDY)
  7. Neuroprotective effects of Natural compounds on ADF/cofilin-actin rod formation in human primary neurons. PhD Student: Gloria Castellano-Gonzales)

Neuro_Group
Last Updated on Monday, 01 November 2010 15:52